Cortexyme (NASDAQ:CRTX – Get Rating) and Genocea Biosciences (NASDAQ:GNCAQ – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability.

Earnings & Valuation

This table compares Cortexyme and Genocea Biosciences' gross revenue, earnings per share and valuation.

Genocea Biosciences has higher revenue and earnings than Cortexyme. Cortexyme is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Cortexyme and Genocea Biosciences, as provided by MarketBeat.

Cortexyme presently has a consensus target price of $15.00, suggesting a potential upside of 1,517.08%. Given Cortexyme's higher probable upside, equities analysts plainly believe Cortexyme is more favorable than Genocea Biosciences.

Insider and Institutional Ownership

63.2% of Cortexyme shares are owned by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are owned by institutional investors. 27.9% of Cortexyme shares are owned by insiders. Comparatively, 1.6% of Genocea Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Cortexyme and Genocea Biosciences' net margins, return on equity and return on assets.

Volatility and Risk

Cortexyme has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.99, meaning that its share price is 99% more volatile than the S&P 500.

Summary

Genocea Biosciences beats Cortexyme on 6 of the 10 factors compared between the two stocks.

About Cortexyme

(Get Rating)

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

About Genocea Biosciences

(Get Rating)

Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The firm uses its proprietary technology platform, ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-011, an investigational adoptive T cell therapy and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.

Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.